FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease – Bio Tech Winners


Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.



Source link

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *